Syncom Formulations (India) Limited

NSE SYNCOMF.NS

Syncom Formulations (India) Limited EBITDA for the year ending March 31, 2024: USD 5.16 M

Syncom Formulations (India) Limited EBITDA is USD 5.16 M for the year ending March 31, 2024, a 24.16% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Syncom Formulations (India) Limited EBITDA for the year ending March 31, 2023 was USD 4.15 M, a -1.29% change year over year.
  • Syncom Formulations (India) Limited EBITDA for the year ending March 31, 2022 was USD 4.21 M, a -31.56% change year over year.
  • Syncom Formulations (India) Limited EBITDA for the year ending March 31, 2021 was USD 6.15 M, a 111.84% change year over year.
  • Syncom Formulations (India) Limited EBITDA for the year ending March 31, 2020 was USD 2.90 M, a 19.20% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
SV Wall Street
NSE: SYNCOMF.NS

Syncom Formulations (India) Limited

CEO Mr. Kedarmal Shankarlal Bankda M.Com
IPO Date Nov. 18, 2022
Location India
Headquarters 207, Saket Nagar
Employees 998
Sector Healthcare
Industries
Description

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.

Similar companies

VIKASLIFE.NS

Vikas Lifecare Limited

USD 0.04

-5.58%

TIRUPATIFL.NS

Tirupati Forge Limited

USD 0.51

-4.25%

STEELXIND.NS

Steel Exchange India Limited

USD 0.11

-2.31%

PCBL.NS

PCBL Limited

USD 4.29

-4.88%

SUKHJITS.NS

The Sukhjit Starch & Chemicals Limited

USD 2.41

-8.81%

StockViz Staff

February 12, 2025

Any question? Send us an email